NEW YORK — Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer of Prevail, will participate in the following virtual investor conferences in November and December:

• Rebranding to Sio Gene Therapies to reflect an independent company with a scientific strategy focused on disease-modifying and curative genetic medicines
• Company’s common stock will trade on the NASDAQ under new ticker “SIOX” effective November 13, 2020

Abbott has begun the U.S. launch of its first company-developed radiofrequency ablation system, designed to target and burn out specific nerves with heat energy to prevent pain signals from reaching the brain.

Fresh off a $91.5 million round, RNA-editing biotech Korro Bio has a new CEO. Ram Aiyar, Ph.D., comes on board after engineering the $2.1 billion acquisition of his previous company, Corvidia Therapeutics, by Novo Nordisk.

Dementia with Lewy bodies (DLB) may be among the most common types of dementia, but there aren’t many treatment options for the disease. EIP Pharma is one step closer to changing that, with phase 2 data showing its prospect beat placebo at boosting cognition in 91 patients. It hopes to kick off a phase 3 trial in late 2021.

Sanofi hit pause on the development program for fitusiran, its Alnylam-partnered RNA-silencing hemophilia treatment, thanks to new side effects seen in clinical trials, a trio of hemophilia organizations announced on Friday.

RemeGen has raised $515 million on the Hong Kong exchange in one of the largest biotech IPOs ever produced.

Launched in 2015 to tackle hearing loss broadly, Decibel Therapeutics kicked off 2020 with a new CEO and an R&D makeover. Nine months later, it’s grabbing $82 million to propel its lead programs into and through the clinic, including a gene therapy for children with congenital deafness and a program left over from its early days designed to protect hearing in cancer patients undergoing chemotherapy.

Denmark’s Novo Nordisk is acquiring New Jersey-based Emisphere Technologies in a deal worth about $1.8 billion. Novo Nordisk specializes in diabetes-related therapeutics. Emisphere is a drug delivery company, with products such as Eligen B12, the first and only once-daily oral non-prescription medical food to normalize B12 levels without injection.

AstraZeneca’s Brilinta (ticagrelor) was approved by the U.S. Food and Drug Administration to reduce the risk of stroke in patients with acute ischemic stroke or high-risk transient ischemic attack (TIA).